DiaMedica Therapeutics Achieves Significant Progress Across Pipeline, Highlights Positive Interim Results for Preeclampsia Program
DiaMedica Therapeutics recently concluded a productive year across its pipeline, achieving key milestones and delivering promising results. The company's President and Chief Executive Officer, Rick Pauls, highlighted the progress made in 2025 during the fiscal year's earnings conference call.
In his opening remarks, Mr. Pauls emphasized that DiaMedica's lead candidate, DM199, is uniquely suited to address vascular pathology associated with various indications, including preeclampsia and acute ischemic stroke. The recombinant form of KLK1 protein has the potential to enhance blood flow and vascular health through its mechanism of action.
Dr. Julie Krop, Chief Medical Officer, took over from Mr. Pauls to discuss the company's progress in its preeclampsia program. In July 2025, DiaMedica announced positive interim results from part I-A of its investigator-sponsored phase II trial being conducted in South Africa. The data demonstrated statistically significant reductions in blood pressure and uterine artery pulsatility index, consistent with improvements in vascular resistance.
The interim analysis revealed clear dose-dependent and sustained reductions in both systolic and diastolic blood pressure, underscoring DM199's potential to control maternal hypertension associated with preeclampsia. Additionally, the results showed that DM199 significantly reduced the uterine artery pulsatility index, indicating improved uteroplacental perfusion.
One of the most significant advantages of DM199 is its inability to cross the placental barrier, placing it in a unique position with respect to safety and reduced fetal risk. This advantageous safety profile, combined with DM199's novel mechanism of action, may enable earlier initiation and longer treatment duration, potentially leading to meaningful prolongation of pregnancy without added safety burden.
The observed improvements in vascular resistance reflect restoration of normal endothelial function consistent with an on-target mechanistic response to DM199 therapy. By improving endothelial health, DM199 has the potential to address the underlying vascular dysfunction driving the disease and stabilize maternal vascular pathology, as opposed to current therapies that merely manage symptoms.
These results demonstrate the promise of DiaMedica's lead candidate in addressing preeclampsia and its associated complications. With a solid foundation established through 2025, the company is poised for further progress in its pipeline and the development of innovative treatments for vascular-related diseases.
